Clinical trials: SARS
COVID-19 (Healthy Volunteers)
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older
The primary objectives of the study were: To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group.
- Trial name
- NCT04537208
- Testing
- CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose)
- Where
- 11 sites in United States
- Volunteers
- 441 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19
Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ/Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04352608
- Testing
- Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
- Where
- China
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19 (Healthy Volunteers)
Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)
This study is to assess the safety, reactogenicity and immunogenicity of a SK SARS-CoV-2 recombinant protein subunit vaccine (NBP2001) in healthy adults.
- Trial name
- NCT04760743
- Testing
- NBP2001 adjuvanted with alum (RBD 30μg/dose), NBP2001 adjuvanted with alum (RBD 50μg/dose), Normal Saline
- Where
- 2 sites in South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
SARS-CoV-2, COVID-19
COVID-19 Among Healthcare Workers in Belgian Hospitals
Due to the situation this study, originally planted until September 2020, was extended with 7 months until April 2021. This extension was approved by the ethical committee University hospital Ghent, Belgium.
- Trial name
- COVHECBEHO (NCT04373889)
- Where
- Belgium
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Sciensano
Covid19, COVID-19 Prevention
Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19
COVID-19 affected more than 9 million of people with more than 130 thousand death in India. If adequate preventive and therapeutic measures are not taken, India has very high risk of affecting million of more people with high…
- Trial name
- PEP-CQ (NCT04858633)
- Testing
- Hydroxychloroquine (HCQ), Standard care
- Where
- India
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
COVID - 19
Safety and Immunogenicity of a Chimeric Recombinant Covid19 Vaccine SpiN-Tec MCTI UFMG
SpiN-Tec MCTI UFMG will be used as a vaccine booster against COVID-19 and will be evaluated using the active comparator, a vaccine approved by ANVISA (Brazilian Health Regulatory Agency).
- Trial name
- SpiN-Tec-001 (NCT07134725)
- Testing
- SpiN-Tec MCTI UFMG, Active Comparator: Covishield® vaccine, Active Comparator: Comirnaty® vaccine
- Where
- Brazil
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Sars-CoV2
COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic
The epidemic due to the Sars-CoV2 virus is spreading in France, without knowning precisely since when the virus has actually circulated on the territory.
- Trial name
- SEROCOV (NCT04304690)
- Testing
- blood sample
- Where
- France
- Volunteers
- 1,177 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SARS CoV 2 Infection
A Study of EDP-235 in Healthy Subjects
This study is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-235 in healthy adult subjects.
- Trial name
- NCT05246878
- Testing
- EDP-235
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
COVID-19
PROLIFIC ChemoprophylaxisTrial (COVID-19)
The number of confirmed cases of COVID-19 infectious disease arising from the SARS-CoV-2 coronavirus is rising substantially and rapidly, with the potential to overwhelm the ability of the entire National Health Service (NHS) to…
- Trial name
- NCT04352933
- Testing
- Hydroxychloroquine - Daily dosing, Hydroxychloroquine - Weekly Dosing
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
COVID-19
A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine
Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or…
- Trial name
- NCT05067933
- Testing
- VXA-CoV2-1.1-S
- Where
- 4 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Vaxart
SARS-CoV-2, Covid19
COVID-19 Child Health Investigation of Latent Disease in Hamburg
The study measures infection rates and the presence of antibodies for SARS-CoV-2 (COVID-19) among in- and outpatients of all pediatric hospitals, as well as volunteers aged 0 to 18 years in Hamburg, Germany.
- Trial name
- C19CHILD (NCT04534608)
- Where
- Germany
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
COVID-19
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with…
- Trial name
- NCT04333225
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Chronic Kidney Disease 5D, Chronic Kidney Disease 5T
Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases
Coronavirus 2019 (COVID-19) infection is associated with higher morbidity and mortality in adult patients on dialysis, and kidney transplant recipients (KTRs).
- Trial name
- NCT05465863
- Testing
- SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
COVID 19 Vaccine
Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)
300 adults ≥30 years of age who have previously received two doses of an inactivated COVID-19 vaccine at least 3 months earlier will receive a third dose with an mRNA vaccine (BNT162b2, BioNTech).
- Trial name
- NCT05057182
- Testing
- BNT162b2
- Where
- Hong Kong
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Covid19
Evaluation of a COVID-19 Pneumonia CXR AI Detection Algorithm
This study investigates the diagnostic performance of an AI algorithm in the detection of COVID-19 pneumonia on chest radiographs.
- Trial name
- NCT04561024
- Testing
- AI model
- Where
- Hong Kong
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Ensemble Group Holdings, LLC
SARS-CoV-2, Safety
The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine
This study plans to enrol 1000 participants 18 years and above, with ≥10% participants ≥60 years old. According to SARS-CoV-2 vaccine vaccination history, they will be evenly divided into 2 groups, Group A and Group B.
- Conditions
- SARS-CoV-2, Safety, Immunotoxicity
- Trial name
- NCT05492643
- Testing
- one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006), Cellular Immunity, Humoral Immunity
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
COVID-19, SARS-CoV-2
Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.
Translational, prospective / retrospective, non-profit, non-pharmacological study, with cohort characteristics. The study consists of two parts: the first to study epidemiological aspects of the spread of the disease and the…
- Trial name
- CORSA (NCT04345315)
- Testing
- serological test, Rapid molecular test, Next generation Sequencing (NGS) analysis
- Where
- 2 sites in Italy
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), HIV
COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV
This observational study will prospectively characterize the long-term symptoms and side effects of COVID-19 in cohorts of people living with and without HIV.
- Trial name
- NCT04958889
- Testing
- No intervention
- Where
- United States
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
SARS-CoV-2
Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster
This study is to evaluate the safety and immunogenicity of a SARS-CoV-2 mRNA Vaccine as a heterologous booster dose in adults who completed 2 doses of inactivated vaccination through 12 months in China.
- Trial name
- NCT05897190
- Testing
- SARS-CoV-2 mRNA vaccine (RBMRNA-405), CoronaVac®
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Argorna Pharmaceuticals Co., LTD
Reactive Axillary Lymphadenopathy for SARS-CoV-2 Vaccines in the Asian Taiwanese Population
Sonography for COVID-19 Vaccines Related Reactive Lymphadenopathy
This study aimed to provide vast clinical information to facilitate breast sonographic examination for participants who underwent recent SARS-CoV-2 vaccination.
- Trial name
- NCT06429020
- Testing
- the AstraZeneca ChAdOx1 (AZ) vaccine, Moderna mRNA-1273 (Moderna) vaccine, and Pfizer-BioNTech BNT162b2 (BNT) vaccine.
- Where
- Taiwan
- Volunteers
- 1,089 people, healthy volunteers welcome
- Sponsor
- Chimei Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.